In Silico and In Vitro Screening of Hydrazone-Based Kinase Inhibitors for Anti-Proliferative Activity in Hormone Receptor-Positive Breast Cancer
DOI:
https://doi.org/10.5281/zenodo.22644239Keywords:
hydrazone kinase inhibitors, hormone receptor-positive breast cancer, molecular docking, MCF-7 anti-proliferative activity, in silico ADMET screeningAbstract
Background: Hormone receptor-positive (ER+/PR+) breast cancer accounts for the majority of the more than two million new
breast cancer diagnoses made annually worldwide, and acquired resistance to endocrine therapy is frequently driven by
compensatory activation of EGFR, PI3K/AKT/mTOR, and cyclin-dependent kinase (CDK) signaling that cross-talks with the
estrogen receptor. Objective: This narrative review synthesizes the published literature on hydrazone-based kinase inhibitor
chemotypes evaluated by molecular docking and in vitro anti-proliferative testing against hormone receptor-positive breast cancer
models, principally the MCF-7 cell line. Methods: Peer-reviewed studies describing hydrazone or hydrazide-hydrazone derivatives
designed against EGFR, CDK2, mTOR, or the estrogen receptor and profiled by in silico docking, ADMET prediction, and in vitro
cytotoxicity were identified and narratively synthesized around synthetic strategy, kinase target rationale, in silico screening
methodology, and structure-activity relationships. Findings: Hydrazone chemotypes built on indole, isatin, thiazole, benzimidazole,
quinoline, and pyrazole cores have been docked against EGFR (including the T790M/L858R resistance mutant), CDK2, mTOR, and
the estrogen receptor ligand-binding domain, with binding energies for lead compounds reaching approximately -11 to -12
kcal/mol. Reported anti-proliferative potencies against MCF-7 and related lines span single-digit nanomolar to double-digit
micromolar concentrations, with several lead compounds achieving selectivity indices exceeding conventional cytotoxic reference
agents and mechanistic evidence of apoptosis induction and cell-cycle arrest. Conclusions: Hydrazone-based kinase inhibitors
represent a chemically versatile and pharmacologically promising class of candidate agents for hormone receptor-positive breast
cancer, and further head-to-head structure-activity optimization against hormone receptor-positive and hormone
receptor-negative models within single studies is warranted to advance this compound class toward more definitive preclinical
validation.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3):229-263, DOI:10.3322/caac.21834.
Massarweh S, Schiff R (2006) Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocrine-Related Cancer, 13(Suppl 1):S15-S24, DOI:10.1677/erc.1.01273.
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Dieras V, Slamon DJ (2016) Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 375(20):1925-1936, DOI:10.1056/NEJMoa1607303.
Nabieva N, Fasching PA (2023) CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. Cancers, 15(6):1763, DOI:10.3390/cancers15061763.
Ozil M, Onelge E, Emirik M, Acikalin Coskun K, Tutar Y (2026) Trifluoromethyl-Benzimidazole-Hydrazone Derivatives as Promising Selective Anticancer Agents: Synthesis, Cytotoxicity, and Molecular Docking Insights. Pharmaceuticals, 19(8):1270, DOI:10.3390/ph19081270.
Farghaly TA, Abbas EMH, Al-Soliemy AM, Sabour R, Shaaban MR (2022) Novel sulfonyl thiazolyl-hydrazone derivatives as EGFR inhibitors: Design, synthesis, biological evaluation and molecular docking studies. Bioorganic Chemistry, 121:105684, DOI:10.1016/j.bioorg.2022.105684.
Tao Y, Guo K, Liao X, Yan G (2026) Design, Synthesis, Bioactivity, and Docking Studies of Isatin-Hydrazone Derivatives as Potential CDK-2 Inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 26, DOI:10.2174/0118715206420750251029040513.
Eldehna WM, Elsayed ZM, Elnagar MR, Omar YM, Abdulla MH, Saleh AM, Shalabi AR, Elimam DM, Alshamari S, Fares M, Tawfik HO (2026) Targeting CDK-2 With Novel Indole-Pyrazole Hybrids: Discovery of Potent Anticancer Agents Supported by Mechanistic and In Silico Studies. Drug Development Research, 87(5):e70357, DOI:10.1002/ddr.70357.
Aljuhani A, Nafie MS, Albujuq NR, Alsehli M, Bardaweel SK, Darwish KM, Alraqa SY, Aouad MR, Rezki N (2025) Discovery of new benzothiazole-1,2,3-triazole hybrid-based hydrazone/thiosemicarbazone derivatives as potent EGFR inhibitors with cytotoxicity against cancer. RSC Advances, 15(5):3570-3591, DOI:10.1039/D4RA07540D.
Bondock S, Alabbad N, Hossan A, Abdou MM, Shati AA, Alfaifi MY, Elbehairi SEI, Mohamed NM (2024) Design, synthesis, and anticancer evaluation of novel coumarin/thiazole congeners as potential CDK2 inhibitors with molecular dynamics. RSC Advances, 14(27):18838-18855, DOI:10.1039/d4ra02456g.
Ghaffar U, Khan F, Hussain J, Mali SN, Khan A, Chaudhari SY, Jawarkar RD, Alanazi AK, Islam WU, Ismail MA, Al-Harrasi A, Shafiq Z (2025) In-vitro and in-silico study to assess anti breast cancer potential of N-tosyl-indole based hydrazones. Scientific Reports, 15:35733, DOI:10.1038/s41598-025-21326-6.
Munir I, Batool Z, Khan F, Hussain J, Khan A, Mali SN, Radhakrishnan VV, Mathew B, Almutairi TM, Al-Harrasi A, Akram MS, Shafiq Z (2025) Design, synthesis, in vitro, and in silico studies of novel isatin-hybrid hydrazones as potential triple-negative breast cancer agents. RSC Advances, 15(2):948-965, DOI:10.1039/d4ra07650h.
Lu JX, Lan HR, Zeng D, Song JY, Hao YT, Xing AP, Shen A, Yuan J (2025) Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives. RSC Advances, 15(1):231-243, DOI:10.1039/D4RA06954D.
Demirci ZZ, Akgun E, Akalin Ciftci G, Yurttas L (2026) Investigation of the In Vitro and In Silico Anticancer Potential of Novel 4-Arylthiazole-Hydrazone Derivatives. Chemical Biology & Drug Design, 108(3):e70387, DOI:10.1111/cbdd.70387.
Verma S, Lal S, Narang R (2024) Expanding potential of quinoline hydrazide/hydrazone derivatives as anticancer agents. Future Medicinal Chemistry, 16(13):1283-1286, DOI:10.1080/17568919.2024.2366150.
Kumar D, Kumar NM, Ghosh S, Shah K (2012) Novel bis(indolyl)hydrazide-hydrazones as potent cytotoxic agents. Bioorganic & Medicinal Chemistry Letters, 22(1):212-215, DOI:10.1016/j.bmcl.2011.11.031.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1-3):3-26, DOI:10.1016/S0169-409X(00)00129-0.
Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7:42717, DOI:10.1038/srep42717.
Pinzi L, Rastelli G (2019) Molecular Docking: Shifting Paradigms in Drug Discovery. International Journal of Molecular Sciences, 20(18):4331, DOI:10.3390/ijms20184331.
